Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03592088 in Relapsed or Refractory AML or CMML
NCT03922100Phase 2Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Apr 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of NMS-03592088 in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Nerviano Medical Sciences. Started Apr 2019; status: terminated.
02
Drugs
NMS-03592088
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03922100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922100.